ZVRAZevra Therapeutics, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~6% a year FCF growth. The price demands less than its three-year revenue growth of 102% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ZVRA's price assumes
Zevra Therapeutics, Inc. trades at 12.0× earnings against 18.6× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 18.6 · cheaper than the typical name in its group
- Free cash flow yield
- 5.0%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; revenue has grown +102% a year over the last three.
Details›
- Healthcare median P/E509 names
- 26.0
- Biotechnology median P/E244 names
- 18.6
- Free cash flow, trailing twelve months
- $33M
- Market capitalisation
- $650M
- 3-year revenue growth
- +102%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.